Amended Statement of Ownership (sc 13g/a)
11 February 2022 - 11:14PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. 2)*
Indaptus
Therapeutics, Inc.
(Name
of Issuer)
Common
Stock, $0.01 par value per share
(Title
of Class of Securities)
45339J105
(CUSIP
Number)
December
31, 2021
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
1.
|
Names of Reporting Persons.
|
|
|
|
Mitchell P. Kopin
|
2.
|
Check the Appropriate Box if a Member of
a Group (See Instructions)
|
|
|
|
(a) ☐
|
|
(b) ☐
|
3.
|
SEC Use Only
|
|
|
|
4.
|
Citizenship or Place of Organization
|
United States of America
|
|
|
|
Number
of
Shares
Beneficially
Owned
by Each
Reporting
Person
With:
|
5.
|
Sole Voting Power
|
0
|
|
|
|
6.
|
Shared Voting Power
|
60,232
|
|
|
|
7.
|
Sole Dispositive Power
|
0
|
|
|
|
8.
|
Shared Dispositive Power
|
60,232
|
|
|
|
|
9.
|
Aggregate Amount Beneficially Owned
by Each Reporting Person
|
60,232 (see Item 4)
|
|
|
|
10.
|
Check if the Aggregate Amount in Row (9)
Excludes Certain Shares (See Instructions) ☐
|
|
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
|
0.7% (see Item 4)
|
|
|
|
12.
|
Type of Reporting Person (See Instructions)
|
|
|
|
|
|
IN; HC
|
|
1.
|
Names of Reporting Persons.
|
|
|
|
Daniel B. Asher
|
2.
|
Check the Appropriate Box if a Member of
a Group (See Instructions)
|
|
|
|
(a) ☐
|
|
(b) ☐
|
3.
|
SEC Use Only
|
|
|
|
4.
|
Citizenship or Place of Organization
|
United States of America
|
|
|
|
Number
of
Shares
Beneficially
Owned
by Each
Reporting
Person
With:
|
5.
|
Sole Voting Power
|
0
|
|
|
|
6.
|
Shared Voting Power
|
60,232
|
|
|
|
7.
|
Sole Dispositive Power
|
0
|
|
|
|
8.
|
Shared Dispositive Power
|
60,232
|
|
|
|
|
9.
|
Aggregate Amount Beneficially Owned
by Each Reporting Person
|
60,232 (see Item 4)
|
|
|
|
10.
|
Check if the Aggregate Amount in Row (9)
Excludes Certain Shares (See Instructions) ☐
|
|
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
|
0.7% (see Item 4)
|
|
|
|
12.
|
Type of Reporting Person (See Instructions)
|
|
|
|
|
|
IN; HC
|
|
1.
|
Names of Reporting Persons.
|
|
|
|
Intracoastal Capital LLC
|
2.
|
Check the Appropriate Box if a Member of
a Group (See Instructions)
|
|
|
|
(a) ☐
|
|
(b) ☐
|
3.
|
SEC Use Only
|
|
|
|
4.
|
Citizenship or Place of Organization
|
Delaware
|
|
|
|
Number
of
Shares
Beneficially
Owned
by Each
Reporting
Person
With:
|
5.
|
Sole Voting Power
|
0
|
|
|
|
6.
|
Shared Voting Power
|
60,232
|
|
|
|
7.
|
Sole Dispositive Power
|
0
|
|
|
|
8.
|
Shared Dispositive Power
|
60,232
|
|
|
|
|
9.
|
Aggregate Amount Beneficially Owned
by Each Reporting Person
|
60,232 (see Item 4)
|
|
|
|
10.
|
Check if the Aggregate Amount in Row (9)
Excludes Certain Shares (See Instructions) ☐
|
|
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
|
0.7% (see Item 4)
|
|
|
|
12.
|
Type of Reporting Person (See Instructions)
|
|
|
|
|
|
OO
|
|
This
Amendment No. 2 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting
Persons with the Securities and Exchange Commission (the “SEC”) on February 11, 2020, as amended by Amendment No. 1
thereto filed by the Reporting Persons with the SEC on January 29, 2021 (the “Schedule 13G”).
Except
as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have
the meanings ascribed to such terms in the Schedule 13G.
Item
1.
(a)
Name of Issuer
Indaptus
Therapeutics, Inc. (the “Issuer”)
(b)
Address of Issuer’s Principal Executive Offices
3
Columbus Circle, 15th Floor
New
York, New York 10019
Item
2.
(d)
Title of Class of Securities
Common
Stock, par value $0.01 per share, of the Issuer (the “Common Stock”).
(e)
CUSIP Number
45339J105
Item
4. Ownership.
(a)
and (b):
As
of the close of business on December 31, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 60,232
shares of Common Stock, which consisted of (i) 5,232 shares of Common Stock issuable upon
exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”) and (iii)
55,000 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant
2”), and all such shares of Common Stock represented beneficial ownership of approximately 0.7% of the Common Stock, based
on (1) 8,193,579 shares of Common Stock outstanding as of November 11, 2021 as reported by the Issuer, plus (2) 5,232 shares of Common
Stock issuable upon exercise of Intracoastal Warrant 1 and (3) 55,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant
2.
(c)
Number of shares as to which each Reporting Person has:
(i)
Sole power to vote or to direct the vote: 0.
(ii)
Shared power to vote or to direct the vote: 60,232.
(iii)
Sole power to dispose or to direct the disposition of 0.
(iv)
Shared power to dispose or to direct the disposition of 60,232.
Item
5. Ownership of Five Percent or Less of a Class
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than 5 percent of the class of securities, check the following þ.
Item
10. Certification
By
signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely
in connection with a nomination under §240.14a-11.
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Date:
February 11, 2022
|
/s/ Mitchell P. Kopin
|
|
Mitchell P. Kopin
|
|
|
|
/s/ Daniel B. Asher
|
|
Daniel B. Asher
|
|
Intracoastal Capital LLC
|
|
|
|
|
By:
|
/s/ Mitchell P. Kopin
|
|
|
Mitchell P. Kopin, Manager
|
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024